Leukaemia Section
Short Communication

t(11;19)(q13;p13) FSTL3/CCND1

Jean-Loup Huret
Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France

Published in Atlas Database: February 2015
Online updated version : http://AtlasGeneticsOncology.org/Anomalies/t1119q13p13FSTL3-CCND1ID1527.html
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/62528/02-2015-t1119q13p13FSTL3-CCND1ID1527.pdf
DOI: 10.4267/2042/62528

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract
Review on t(11;19)(q13;p13) FSTL3/CCND1, with data on clinics, and the genes involved.

Keywords
t(11;19)(q13;p13); FSTL3; CCND1; chronic lymphocytic leukemia

Clinics and pathology

Disease
B-cell chronic lymphocytic leukemia (B-CLL)

Epidemiology
Only one case to date, a 67 year-old female patient (Rimokh et al., 1993; Hayette et al., 1998).

Prognosis
No data

Cytogenetics

Cytogenetics morphological
Complex karyotype.

Genes involved and proteins

CCND1
Location
11q13.3

Protein
Binds and activates the G1 cyclin dependent kinases; Phosphorylates SMAD3 and inhibits its transcriptional activity and antiproliferative function.

FSTL3
Location
19p13.3

Protein
Binds activin A and with lower affinity several other members of the TGF beta family; interacts with ADAM12, FN1 (fibronectin type 1,), and MLLT10 (Grusch, 2012).

Result of the chromosomal anomaly

Hybrid gene

Description
The breaks occurred at nucleotide 2276 in the 3' untranslated region of the last CCND1 exon, and about 7 kbp upstream of FSTL3.

References


This article should be referenced as such: